Navigation Links
Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Date:10/4/2007

y maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...rate research of potential vaccine for low-resourc...Md., Dec. 4 The biotech company Le... organization PATH announced today a partnership t...ine. PATH will initially invest $3 million over 27...lopment of a H5N1 virus-like particle (VLP) protot...
(Date:12/4/2008)...swire-FirstCall/ -- NeoStem, Inc.,(NYSE Alternext...lection,processing and long-term storage of adul...nced that it has reached a major milestone in its ...st ever collection center for collection of,adult...al need in New York,City and has chosen Bruce Yaf...
(Date:12/4/2008)...c. 4 A 60-year-old,pros...e first person in France,to be treated using Rapi...NYSE: VAR ) for fast and precise forms of intens...eatments at the CRLC Val D,Aurelle - Paul Lamarque...faster than conventional IMRT,treatments. Dr. Pas...
(Date:12/4/2008)...s New Trade Name Onrigin(TM) for Laromustine , ...ll/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin B...ted to events in connection with the 50th American...ne Center in San Francisco from December 6-9, 2008..., The Company announced that it would present s...
Breaking Biology Technology:Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 2Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 4Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 4
... was developed at the USDA Forest Products Laborat...ison has been acquired by Xethanol Corp. of New ...TI), was a wholly owned subsidiary of UTEK Corp.,...thanol Corp. is a biotechnology-driven ethanol pro...rough a stock-for-stock exchange. , ,XTI holds a l...
...earch team announced on Sunday they have successfu...in cells, a finding that could affect some of the ...h avenues. But a University of Wisconsin-Madison p...d repercussions. , ,In an article published on the...rchers Chad Cowan, Kevin Eggan and their colleague...
...s made significant progress in improving business ...elieve investment restrictions if the state is to ...te Senate committee heard on Tuesday. , ,"Today it...y than it is to invest in emerging, growth Wiscons...private banker who formerly worked for the Wiscons...
... new UW E-Business Consortium member spotlight ser...y of Wisconsin E-Business Consortium in 2002. , ,...ciate creative appliance design. The brand those v...-Zero Freezer Co. , ,Sub-Zero,s built-in refriger...a home,s dcor, allowing customization to be driven...
Other Biology Technology:Harvard advance improves stem cell research; not a medical revolution 2Regulations still stymie business investment in high-growth companies 2Regulations still stymie business investment in high-growth companies 3Regulations still stymie business investment in high-growth companies 4How Sub-Zero Freezer Co. uses technology to revolutionize customer service 2How Sub-Zero Freezer Co. uses technology to revolutionize customer service 3
(Date:12/3/2008)...R 1, 2008 -- As the United States continues to dev...nergy independence, cellulosic-based ethanol has e...nologies. Corn stover remains the most popular sou... (SOC) associated with the removal of corn fodder ...al and environmental concern. , In the Novembe...
(Date:12/3/2008)...em of children failing to take their medication fo...ackled as part of a new university research projec...ists at The University of Nottingham and The Unive... school children with asthma, diabetes, congenital...riers that prevent them from taking medicines pres...
(Date:12/3/2008)...team of investigators led by researchers at the Ke...n California (USC) has received $19 million in fun... (NIMH) for a groundbreaking effort to collect gen...in order to study the genetic risks for schizophre...Genomic Psychiatry and Massachusetts General Hospi...
(Date:12/3/2008)...E, Mass. Natural changes in voltage that occur ac...powerful controlling factor in the process by whic...earch published by Tufts University scientists. ,...ssor of Biology Michael Levin, and Chair of Biomed...thor) published their paper "Membrane Potential C...
Breaking Biology News(10 mins):Managing carbon loss 2A spoonful of sugar? 2A spoonful of sugar? 3USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 2USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 3New 'control knobs' for stem cells identified 2XTL Biopharmaceuticals to Present at the Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5422 1XTL Biopharmaceuticals to Present at the Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5422 2Going barefoot 3F Beware 21 19426 1Going barefoot 3F Beware 21 19426 2After Effects 3A Giving Back Is Good for You 19422 1After Effects 3A Giving Back Is Good for You 19422 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention Deficit Hyperactivity Disorder 28ADHD 29 2070 1Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention Deficit Hyperactivity Disorder 28ADHD 29 2070 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention Deficit Hyperactivity Disorder 28ADHD 29 2070 3
...such as the Amazon rainforest are home to some 750...5 species in Britain. UCL scientists have ruled ou...of wildlife to climate change, in a paper publishe...e Royal Society B (Biological Sciences). , Instea...eater role in the evolution of species than extern...
...ring an ordinary half-hour argument is enough to s...t least one day, a new study has shown. , Moreove...le toward each other, the delay in that healing pr...dy have major financial implications for medical c..., reported in the current issue of the Archives of...
...tumors by selectively targeting and killing the ma...in the open access journal PLoS Medicine, has appl... (GBM). This is the most aggressive form of brain ...xperienced and killing most patients within a year...zki and colleagues (of The Hebrew University of Je...
...,s AURA satellite, determined the seasonal ozone h...aller than in previous years. , NASA,s 2005 asses... was the first based on observations from the Ozon...craft. Aura was launched in 2004. , This year,s o... peak between September and mid-October, which was...
Other Biology News:Why the Amazon rainforest is so rich in species 2Why the Amazon rainforest is so rich in species 3Stress substantially slows human body's ability to heal 2Stress substantially slows human body's ability to heal 3Preclinical study of a new brain tumor therapy 2NASA's AURA satellite peers into Earth's ozone hole 2
Luminometers
Prolong Gold Antifade Reagent from Invitrogen
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions.
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research
Biology Products: